REPL:NASDAQReplimune Group, Inc. Analysis

Replimune’s stock is trading at $11.51, comfortably above its 20‑day SMA of $10.34 and the longer‑term SMAs, suggesting short‑term bullish momentum, yet the MACD histogram has turned negative and the signal line is bearish, indicating potential downside pressure. The RSI sits at 69, approaching overbought territory, while the price hovers near the upper resistance band of $12.5 and well above the identified support at $8.25. Volume is increasing, but the 30‑day volatility is extreme at nearly 194%, reflecting a highly erratic price environment.
Fundamentally, REPL remains pre‑revenue with zero sales and sizable operating losses (EBITDA around $‑312M). The company holds $269M in cash against $112M of debt, giving a modest cash‑to‑debt cushion, yet free cash flow is deeply negative. The forward PE is negative (‑9.98) and the price‑to‑book ratio of 4.35 appears stretched for a cash‑burning biotech. Recent news highlights that the FDA has accepted a resubmission of the BLA for RP1 and an advisory committee meeting is slated, creating a near‑term catalyst with significant regulatory risk.